Bio-Techne Corporation (TECH)

Market Closed

3 Jun, 20:00

NASDAQ (NGS)

50. 85

+1.08

+2.17%

8.09B Market Cap

49.99 P/E Ratio

0.04% Div Yield

2,111,380 Volume

1.99 Eps

$ 49.77

Previous Close

Investors:

+59

Add Transaction

Day Range

49.03 50.88

Year Range

43.2 72.16

Want to track TECH and more in your Portfolio? 🎯

Get Started For Free

CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 weeks ago

CMB.TECH Q1 Earnings Call Highlights

CMB.TECH NYSE: CMBT reported a strong first quarter of 2026, with management highlighting higher revenue, reduced leverage, lower financing costs and substantial gains from vessel sales during an earnings call titled “Firing on All Cylinders.”

Marketbeat | 2 weeks ago

Bio-Techne Corporation (TECH) Q3 2026 Earnings Call Transcript

Seekingalpha | 4 weeks ago

TECH Stock Falls on Q3 Earnings & Revenue Miss, Operating Margin Up

Bio-Techne slips after Q3 EPS miss and revenue decline, despite operating margin expansion and strong growth in key segments.

Zacks | 4 weeks ago

Techne (TECH) Misses Q3 Earnings and Revenue Estimates

Techne (TECH) came out with quarterly earnings of $0.53 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.56 per share a year ago.

Zacks | 4 weeks ago

All You Need to Know About Techne (TECH) Rating Upgrade to Buy

Techne (TECH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 month ago

CMB.TECH: Valuation Implies Mid-Cycle - Reality Looks Stronger

CMB.TECH is now a highly leveraged play on freight rates, with over 80% spot exposure post-merger and tripled operating scale. Reported EPS is distorted by one-off Golden Ocean deal costs; normalized earnings and EBITDA provide a clearer view of CMBT's true earnings power. CMBT's valuation and investment case hinge on freight rate sensitivity, with current market cap implying mid-to-high cycle TCE rates ($35k–45k/day).

Seekingalpha | 2 months ago

Should You Continue to Hold Bio-Techne Stock in Your Portfolio?

TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and competition cloud near-term outlook.

Zacks | 2 months ago

Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The position was previously 2.3% of the fund's AUM as of the prior quarter.

Fool | 2 months ago